3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2020.01.23
2019年度业绩预告
2020.01.15
关于向银行申请综合授信额度的公告
2020.01.15
第四届董事会第二十八次会议决议公告
2019.12.28
关于首次公开发行境外上市外资股(H股)申请材料获中国证监会受理的公告
2019.12.21
关于控股股东股权质押的公告
2019.12.19
2019年第四次临时股东大会的法律意见书
2019.12.19
2019年第四次临时股东大会决议公告
2019.12.14
关于股东股权解除质押的公告
2019.12.07
第四届董事会第二十七次会议决议公告
2019.12.07
关于延长公司第二期员工持股计划存续期的公告
第一页
上一页
40
41
42
43
44
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.